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Summary
Human platelets, in the absence of antibody, are cytotoxic to tachyzoites of Toxoplasma gondii
as determined by vital staining, transmission electron microscopy, and the failure of Toxoplasma
to survive and replicate in mice after in vitro interaction of the organisms with platelets. Platelet
to T. gondii ratios as low as 1:3 were toxic to the organisms with direct cell-cell contact essential
for platelet-mediated cytotoxicity. Adherence of platelets to T. gondii and disruption of surface
membranes and cytoplasmic contents of the organisms were observed ultrastructurally. Reactive
oxygen species were not implicated in the platelet-mediated toxicity. The interaction of T . gondii
with platelets resulted in a marked increase in thromboxane B2 (TXB2) production compared
with that by unstimulated platelets. The cyclooxygenase inhibitors acetylsalicylic acid and indo-
methacin inhibited platelet-mediated cytolytic activity as did the selective TXA2 synthetase
inhibitor dazmegrel, indicating a role for thromboxane in the platelet-induced cytotoxicity. Further,
toxoplasmacidal activity was retained in the TXA2 synthetase-containing microsomal fractions
of platelets disrupted by freezing and thawing; cytolytic activity was absent in microsome-depleted
platelet supernatant fractions. Both the TXA2-generating platelet microsome system and a stable
TXA2 analogue induced damage to the cellular membranes of the Toxoplasma as noted by
transmission electron microscopy. These findings suggest that platelets may play a role in the
host defense against Toxoplasma and that release of thromboxane may be important in this cytolytic
process.
T
oxoplasma
￿
'gondii is an obligate intracellular protozoan
that actively invades macrophages without triggering
respiratory burst activity, prevents phagolysosomal fusion,
and replicates intracellularly to the detriment ofthe host (1-3).
Toxoplasmosis, the disease caused by this intracellular coc-
cidian parasite, is of increasing concern because of its high
incidence in immunocompromised patients (4). Toxoplasmic
encephalitis is the most common cause of focal central nervous
system lesions in patients with AIDS (5). Parasitemia can be
demonstrated in acute infections (6, 7) and in reactivation
toxoplasmosis in immunocompromised patients (8, 9) . Neu-
trophils (10), monocytes (10, 11), and cytokine (e.g., IFN-
,y)-activated macrophages (11, 12) have cytotoxic activity
against these organisms and contribute toward control of in-
fection.
Recent attention has been directed to the cytotoxic activity
of platelets against various target cells. Platelet-induced
antibody-dependent cell-mediated cytotoxicity (ADCC)'
1 Abbreviations used in this paper . ADCC, antibodrdependent cell-mediated
cytotoxicity; AO, acridine orange; CGD, chronic granulomatous disease;
CTA2, carbocyclic thromboxane A2; EB, ethidium bromide; IFA, indirect
fluorescent antibody; Oz, superoxide anion; PD, phosphate-buffered
saline, Cat'/Mg2*-free; PPACK, D-phenylalari)rl-L-prolyl-L-arginine chloro-
methyl ketone; TX, thromboxane.
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against antibody-sensitized sheep (13, 14) and human (15)
erythrocytes, schistosomula of Schistosoma mansoni (16-18),
and microfilariae ofBrugia malayi (19) has been demonstrated
in vitro. Platelet-mediated ADCC activity resides preformed
in platelet membranes and may involve phospholipase A2
reaction products (20). Whereas mouse platelet-mediated cy-
totoxicity against erythrocytes is dependent upon C3 and IgG
immunoglobulins (13, 14), human platelet-mediated cytotox-
icity against S. mansoni (16), and R malayi (19) is dependent
upon IgE. In addition, IFN-y (18) and C-reactive protein
(17) can each promote platelet killing of schistosomula. Human
platelets are toxic to certain adherent human tumor cell lines
in the absence of antibody (21). This tumoricidal activity is
blocked by inhibitors of arachidonic acid metabolism (21).
Similarly, phospholipase A2 reaction products have been im-
plicated in NK cell-mediated target cell lysis (22-24).
We report here that human platelets are toxic to T . gondii
tachyzoites in the absence of added antibody. Platelet adher-
ence to the surface of the parasites and disruption ofthe sur-
face membranes and internal architecture of the Toxoplasma
were observed. Further, our results suggest a prominent role
for the cyclooxygenase arachidonate metabolite thromboxane
(TX) A2 in this platelet-mediated toxoplasmacidal activity.
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Special Reagents. PG H2 and carbocyclic thromboxane A2
(CTA2) were obtained from Cayman Chemical Co. (Ann Arbor,
MI); human thrombin andD-phenylalanyl-L-prolyl-L-arginine chlo-
romethyl ketone (PPACK), dihydrochloride from Calbiochem-
Behring Corp. (LaJolla, CA); acridine orange (AO) from Allied-
Signal Corp. (MorrisTownship, NJ); acetylsalicylic acid, ethidium
bromide (EB), indomethacin, ferricytochrome c, superoxide dis-
mutase (2,500 U/mg), and EDTA, dipotassium salt from Sigma
Chemical Co. (St. Louis, MO); and glutaraldehyde from Poly-
sciences, Inc. (Warrington, PA). Dulbecco's PBS (0.14 M NaCl,
2.7 x10-1 M KCI, 8.1 x 10 -3 M Na2HPOa, 1.5 x 10-3 M
KH2PO4, 9.0 x 10 -^ M CaC12, and 4.9 x 10 -" M MgC12, pH
7.2) and Cat*/Mg2+-free PBS (PD) were obtained from Gibco
Laboratories (Grand Island, NY). Indomethacin was dissolved in
0.1 ml Tris buffer, pH 8.1, at a concentration of 10"2 M and
diluted with PBS. The selectiveTX synthetase inhibitor, UK38,485
(dazmegrel; 3-(1H-imidazol-1-ylmethyl)-2-methyl-lH-indole-l-pro-
panoic acid) (25) waskindly provided by Dr. P.R. Urquilla (Pfizer,
Inc., Groton, CT). Dazmegrel was dissolved in 0.1 N NaOH in
PBS at a concentration of 10-2 M with dilutions made in PBS.
The final pH of theindomethacin anddazmegrel solutions was7.0.
Toxoplasma gondii.
￿
T . gondii RH strain waskindly provided by
Dr. C.B. Wilson (University of Washington).The Toxoplasma were
maintained by i.p. passage in BALB/c mice as previously described
(26). Organisms were harvestedby peritoneal lavage usingPD, sepa-
ratedfrom leukocytes by filtration througha 3-/Am polycarbonate
filter (Nucleopore Corp., Pleasanton, CA), andcentrifuged at 1,000 g
for 15 min at 4°C. The Toxoplasma were washed twiceby sequen-
tial resuspension in PD and centrifugation at 1,000 g for 15 min
at 4°C. After counting in ahemocytometer, the Toxoplasma were
resuspended in PBS. Aclinical isolate of T. gondii (ERstrain) was
isolated from the brainbiopsy of an adultmale AIDS patient who
had encephalitis. The ER strain Toxoplasma were propagated in
human embryonic tonsil fibroblasts, which were a generous gift
of Dr. Lawrence Corey (Children's Hospital and Medical Center,
Seattle, WA). Afterwashingin PD,theER strain Toxoplasma were
resuspended in PBS. Both the RH and ER strains of Toxoplasma
were >95% viable when assessed by trypan blue dye exclusion (27).
Human Subjects.
￿
Platelets were isolated from the blood of 24
normal human volunteers and 1 patient with chronic granuloma-
tous disease(CGD). In some studies, volunteers ingested 1.3 mg/kg
of acetylsalicylicacid 2 hbefore blood collection to block platelet
formation of cyclooxygenase arachidonate products (28). Other-
wise, the subjects had not taken acetylsalicylicacid or other non-
steroidal antiinflammatory drugs for 2 wk before the study.
Toxoplasma-speck IgG and IgM Antibody Tests.
￿
Each blood
donor wasnegative for Toxoplasma-specific IgGand IgM antibodies
when tested with theindirect fluorescent antibody (IFA)technique
performed according to the manufacturer's recommendations
(Microbiological Research Corp., Bountiful, UT). Briefly, these
tests useRH strain Toxoplasma as theantigensubstratethat is dried
andfixedon microscope slides. After incubation with test serum,
the slides are rinsed andeither fluorescein-conjugated anti-human
IgG (-y chain specific) or fluorescein-conjugated IgM (ti chain
specific) is applied. After a second incubation, the slide is again
rinsed and examined under a fluorescence microscope for the typ-
ical peripheral staining reaction. Thelack of fluorescence at a 1:16
serum IgG-IFA titer and at a 1:8 serumIgM-IFA titer are consid-
ered negative, indicating the lack of prior infection (either acute
or chronic) with T . gondii.
Platelet Isolation.
￿
For platelet isolation, venous blood was col-
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lected in K2EDTA (0.2 ml of 10% K2 EDTA in 10 ml of blood),
diluted 1:1 (vol/vol) with PD and centrifuged at 200g for 15 min
at 4°C. Theplatelet-richplasma was collected andthen centrifuged
at 1,000g for15 minat 4°C. Theresulting platelet pellet waswashed
twiceby sequential resuspension in PD andcentrifugation at 1,000g
for 15 minat 4°C. Aftercounting in ahemocytometer, theplatelets
were resuspended in PBS and used immediately. The preparations
contained <0.05% contamination with nucleated cells.
Platelet-l . gondii Interactions. Duplicate samples of Toxoplasma
(107 organisms/ml) were added to platelets and other components
of the reaction mixtures at the concentrations indicated in the
legends to the figures and tables in polystyrene tubes (12 x 75
mm) in an oscillating water bath at 37°C for 90 min. Duplicate
10-itl samples were taken from each experimental condition after
0-, 60-, 90-min incubations of platelets or disrupted platelet frac-
tions (see below) with T . gondii for assay of viability of the or-
ganisms by trypan blue staining and AO/EB fluorescence micros-
copy. After 90 min of incubation, the reaction mixtures were
centrifuged at 1,000gfor15 minat 4°C and the supernatants col-
lected and stored at -70°C until RIAs for TXB2, PGE2, and
6-keto-PGFI, were performed.
For studies to assess theeffect of antibody on theplateletToxo-
plasma interactions, immune sera were obtained from (a) an asymp-
tomaticindividual with an IgG-IFAtiterof 1:2,048 andanegative
IgM-IFA titer < 1:8 and (b) a patient with acute toxoplasmosis
whohadan IgG-IFA titer of 1:1,024 andan IgM-IFAtiterof 1:512.
Normal serum was obtained from an individual who lacked
Toxoplasma-specific antibodies (i.e., IgG-IFA < 1:16 and IgM-IFA
< 1:8). Fresh normal sera and normal and immune sera that had
been heat-inactivated at 56°C for45 min were used at a 1:10 dilu-
tion (final concentration) in the plateletToxoplasma interactions.
To assess the in vivo survival of Toxoplasma that had been in-
cubated with platelets in vitro, 1-ml reaction mixtures containing
10' T . gondii that had been incubated in the absence or presence
of 10, platelets for 90 min at 37°C were injected into duplicate
pairs ofBALB/c mice. Animals were examined on adailybasis for
survival. Mice stillliving 14 d after injection were classified as sur-
vivors and sacrificed to assess i.p. infection with Toxoplasma.
In some experiments, disruptedplatelet fractionswere substituted
for intact platelets in the reactions with T . gondii. Platelets (2 x
108) in 1 ml were degranulated by treatment with 5 U/ml human
thrombin for 15 min at 37°C (29) with the reaction terminated
by the addition of 10-6 M PPACK (30). Platelets (6 x 108) in 3
ml ofPBSwere also disruptedby threecycles of freezing at -70°C
for 15 min followed by thawing in a 37°C shaking waterbath for
15 min over a 90-min period as previously described (14). The en-
tire contents of thefrozen and thawed plateletswere used in some
experiments or comparably disrupted samples were centrifuged at
5,000g for 15 min at 4°C forremovalofcellular debris. Thesuper-
natant was centrifuged at 100,000 g for 60 min at 4°C as previ-
ouslydescribed (31, 32) to obtain a microsome-depleted superna-
tant and a microsome-containing particulate fraction which was
suspended in 3 ml PBS.
In other studies, intact platelets and T . gondii were cocultured
in individual chambers separatedby a0 .4-Am polycarbonatemem-
branein a6-well (24-mm-diam) Transwellplate(CostarData Pack-
aging Corp., Cambridge, MA). Toxoplasma (2 x 107) were added
to 2 ml PBS in the bottom chamber and platelets (2 x 107) in
2 ml PBSwere placed in the upper chamber. Theplates were cen-
trifuged at 1,000g for 30 min at 20°C to facilitate exchange of
mediabetween thechambers and then incubated an additional 60
min at 37°C before assay of T. gondii viability.
AssayofT . gondii Viability.
￿
Viability of T . gondii wasdeterminedby trypanblue staining (27) andfluorescence microscopy.Differential
fluorescence ofviable andnonviable T . gondiiwasexamined by reac-
tion with AO and EB as previously described (33). Each sample
was mixed with an equal volume of an AO (2.5 wg/ml)/EB
(5 Ag/ml) solution before placementon aglass slide in preparation
for fluorescence microscopy using an Olympus Vanoxmicroscope
with epiilluminator (Olympus Corporation ofAmerica, NewHyde
Park, NY). Toxoplasma were countedat 200x magnificationusing
amicrometer disc (Bausch&Lomb Inc., Rochester, NY)containing
64 grids (total grid area = 2,000 hm2); 10 random fields were
selected foreach sample. Viable organisms demonstrated a bright
green nuclear fluorescence, whereas nonviable Toxoplasma were
orange.
Transmission Electron Microscopy.
￿
Pellets of 2 x 10' T . gondii in-
cubatedwith the various components of the reaction mixture(see
legends to figures) were collected by centrifugation, fixed in 2%
glutaraldehyde, andprepared fortransmission electron microscopy
as previously described (34). The samples were examined with a
JEOL 100B electron microscope QEOL USA, Electron Optics Di-
vision, Medford, MA) at 60 kV
Superoxide AnionAssay .
￿
Superoxide anion (OZ) generation was
measured by thecapacity ofOZ to reduce ferricytochrome c to fer-
rocytochrome cin a microassay system as previously described(35).
In brief, the 0.2-mlreaction mixtureconsistedofPBS, 8% albumin,
54.5 uM ferricytochrome c, 107 platelets, and the presence or ab-
sence of 106 T . gondii. The reactions were performed in quadru-
plicate wells of 96-well microtiter plates (Costar Data Packaging
Corp., Cambridge, MA) in thepresence or absence of 62.5 Jig/ml
superoxide dismutase for 90 min at 37°C. Nanomoles of fer-
ricytochrome creduced were calculated from themaximalincrease
in absorbance measured at 550nm in amicrotiter platereader (model
309; BioTek Instruments, Inc., Burlington, VT).
RIAs.
￿
PGEZ and the respective stable hydrolysis products of
PGIZ and TXAZ, 6-keto-PGFI~ and TXBZ, were assayed by RIA.
The PGEZ, 6-keto-PGFI., and TXBZ antisera were produced in
Table 1.
￿
Toxoplasmacidal Activity ofHuman Platelets
67
￿
Yong et al.
rabbits in our laboratory and their cross-reactivities have been
reported (36, 37). The PGEZ antiserum at a dilution of 1:6,000
had a sensitivity of 10 pg per 0.1-ml sample, the 6-keto-PGFI,an-
tiserum at a 1:6,000 dilution had a sensitivity of 10 pg per0.1-ml
sample, and the TXBZ antiserum at a dilution of 1:100,000 had
a sensitivity of 1 pg per 0.1-ml sample. Synthetic standards were
the generous gift ofDouglas McCarter (UpjohnCo., Kalamazoo,
MI). Labeled tracers (fH]PGEZ, fH]6-keto-PGFI«, and fH]TXB2)
were obtained from NewEngland Nuclear(Boston, MA) andun-
labeled syntheticprostanoid standardswere obtained from Cayman
Chemical Co. Each assaywas performedin duplicate accordingto
standard protocols.
Statistical Analysis.
￿
The data are reported as the mean ± SE
of the combined experiments. Differences were analyzed for
significance (p < 0.05) by Student's two-tailed ttest for indepen-
dent means.
Results
Platelet-mediated Cytotoxicity against T . gondii.
￿
Incubation
of T . gondii (RE strain) for 90 min at pH 7.0 with intact
humanplatelets in theabsenceof serumresulted in asignificant
increase in nonviability of the Toxoplasma to 18.9% from a
background of 6.4% under the conditions used in Table 1.
The platelet (effector)/Toxoplasma (target) cell ratiowas 1:3.
Toxicity as assessed by trypan blue staining and by orange
fluorescence of theorganismsupon vital staining with AO/EB
increasedprogressively with higher ratios ofplateletsto Toxo-
plasma up to 84.7% nonviability of the organisms at a 100:1
ratio(Table 1) . Humanplateletshad a similar cytotoxiceffect
against a T .gondii strain that hadbeen isolated from apatient
with AIDS; 60.3, 37.0, and 18.9% of these organisms were
The reaction mixture contained 2 x 107 T. gondii (Toxo; RH strain [RH] or clinical isolate ER strain [ER]) alone or with 0.67 x 107 to 2 x
109 human platelets as indicated in a totalvolume of 2 ml PBS. Viability of T. gondii was assessed by trypan blue staining and confirmed by AO/EB
fluorescence microscopy after 0-, 60-, or 90-min incubations at 37°C.
Mean t SE of experiments (n). Probability (p) values for the difference from T. gondii (RH strain or clinical isolate) alone are shown where sig-
nificant (p < 0.05).
Supplements 0 min
Nonviable T .
60 min
gondii
90 min
p / 00 1 p
Toxo (RH) 3.7 ± 0.8 (8)' 6.3 ± 1.5 (8) 6.4 ± 1.5 (8)
Platelets + Toxo (RH) (1:3) 4.0 ± 0.8 (8) 12.5 ± 1.5 (8) <0.02 18 .9 ± 1.6 (8) <0.001
(1:1) 3.2 ± 1.5 (3) 26.4 ± 2.6 (3) <0.001 40.5 ± 8.2 (3) <0.001
(10:1) 3.1 ± 1.8 (3) 34.6 ± 2.9 (3) <0.001 60.6 ± 9.1 (3) <0.001
(100:1) 3.6 ± 2.0 (3) 65.6 ± 3.8 (3) <0.001 84 .7 ± 0.3 (3) <0.001
Toxo (ER) 3.6 ± 0.3 (3) 4.1 ± 0.9 (3) 7.5 ± 1.5 (3)
Platelets + Toxo (ER) (1:3) 5.3 ± 1.2 (3) 16.6 ± 2.6 (3) <0.02 18 .9 ± 1.3 (3) <0.01
(1:1) 5.4 ± 1.1 (3) 29.1 ± 5.2 (3) <0.01 37 .0 ± 2.5 (3) <0.001
(10:1) 3.8 ± 1.6 (3) 42.9 ± 1.3 (3) <0 .001 60.3 ± 5.3 (3) <0.001nonviable after 90 min of incubation of platelets with Toxo-
plasma at ratios of 10:1, 1:1, and 1:3, respectively (Table 1) .
Platelet-mediated toxoplasmacidal activity wasnot affected
by the presence of either heat-inactivated (Table 2) or fresh
(data not shown) normal serum that was negative for
Toxoplasma-specific IgG and IgM antibodies . Further, heat-
inactivated immune sera that contained Toxoplasma-specific
IgG antibodies in either the absence or presence of Toxoplasma-
specific IgM antibodies did not alter platelet-induced Cyto-
toxicity against T . gondii (Table 2) . Freshimmune serumwas
not used since, as reported by other investigators, Toxoplasma-
specific antibody in the presence of complement has a Cyto-
toxic effect against the organisms (38-41) .
To assess whetherthedemonstrated in vitro cytotoxic effect
ofplatelets against Toxoplasma corresponded to decreased via-
bility of the organisms in vivo, T . gondii alone and platelet-
T . gondii (10:1 ratio) reaction mixtures (each containing 101
organisms) after in vitroincubation for 90min at 37°C were
injected intrapentoneally into BALB/c mice; theanimalswere
followed for survival and recovery of viable organisms over
a 2-wk study period . All control animals injected with
T . gondii alone (n = 8) died within 5 d after injection . In
contrast, 100% oftheanimals receiving the platelet-T gondii
suspensions (n = 8) survived the 14-d study period . Toxo-
plasma were recovered at necroscopy from the peritoneal fluid
of each of the mice that had receivedT . gondii alone but were
absent in the peritoneal fluid of the survivors that were
sacrificed on day 14 .
Direct cell-cell contactwas essential forplatelet-mediated
toxoplasmacidal activity. Separation of platelets from Toxo-
plasma by a0.4-Am polycarbonatemembrane barrier in a tissue
culture well blocked in vitro platelet-mediated toxoplasma-
cidal activity (Fig . 1) .
Platelet-mediated cytotoxicity against T . gondii was con-
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Figure 1 .
￿
Effect of a membrane barrier on platelet-mediated cytotox-
icity against T . gondii. 2 x 107 T . gondii were incubated in tissue culture
wells alone or with 2 x 107 platelets (Pits) in the absence or presence
of a 0.4-,um polycarbonate membrane barrier for 90 min at 37°C. Via-
bility ofthe organisms was determined as described in Table 1 . The data
represent the mean ± SE of three experiments. Probability values for the
difference from T . gondii alone are shown where significant (p < 0.05) .
firmedby transmission electron microscopy. Greaterthan90%
of Toxoplasma incubated inPBSfor 90minexhibitedtheusual
morphology of viable tachyzoites (42) . The crescent shaped
T . gondii have a continuous outer surface membrane (Fig . 2
The reaction mixtures contained 2 x 10 7 T. gondii (Toxo ; RH strain) in the absence or presence of 2 x 107 platelets in 2 ml PBS . In some studies
as described in Materials and Methods, normal serum (IgG-IFA <1:16/IgM-IFA <1:8 [IgG-/IgM-]) or immune serum (IgG-IFA=1:2,048/IgM-
IFA <1:8 [IgG+/IgM -] or IgG-IFA=1:1,024/IgM-IFA=1 :512 [IgG'/IgM+]) that had been previously heat inactivated at 56'C for 45 min was
included at a 1 :10 dilution (final concentration) . The reaction mixtures were incubated for 90 min at 37°C with parasite viability determined as
described in Table 1 .
' Mean ± SE of three experiments . Probability (p) values for the difference from T. gondii alone are shown where significant (p < 0.05) .
Table 2. Effect of Toxoplasma-specific Antibodies on Platelet-mediated Toxoplasmacidal Activity
Nonviable T. gondii
Supplements 0 min 90 min
91 0 01 P
Toxo 3.0 ± 1 .1"' 6 .9 ± 0.6
+ normal serum (IgG-/IgM- ) 4.7 ± 1.8 6 .9 ± 0.1
+ immune serum (IgG'/IgM- ) 4.4 ± 1.4 10.8 ± 2.4
+ immune serum (IgG'/IgM+) 5.5 ± 1.3 10 .6 ± 1 .4
Platelets + Toxo 4.5 ± 1.6 44.5 ± 7.6 <0.01
+ normal serum (IgG-/IgM- ) 5.7 ± 2.3 45 .5 ± 2.0 <0.001
+ immune serum (IgG+/IgM- ) 4.9 ± 1.2 42.4 ± 3 .0 <0.001
+ immune serum (IgG'/IgM+) 4.9 ± 1.3 44.9 ± 8.2 <0.01A) beneath which is located an innermembranous layer that
is interrupted at the anterior and posterior ends of the or-
ganisms . The nucleus and intracellular organelles such as Golgi
apparatus, mitochondria, and endoplasmic reticulum of the
T . gondii appeared normal in the control Toxoplasma (Fig. 2
A) . The human platelets also exhibited their typical mor-
phology (43) when incubated in PBS for 90 min . Smaller
than Toxoplasma, platelets have a single unit plasma mem-
brane and cytoplasmic granule heterogeneity with both ci
and dense granules present (Fig. 2 B) . The control platelets
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Figure 2 . Ultrastructure of T .
gondii and platelets. (A) Toxoplasma
gondii were incubated in the stan-
dard salt solution for 90 min at
37°C as described in Table 1 . The
normal appearance of the Toxo .
plasma (TOXO) with their elongate
and crescent appearance is shown .
The usual array of cytoplasmic or-
ganelles is seen including Golgi ap-
paratus (G), mitochondria (M), and
nucleus (N) . The surface membrane
ofthe Toxoplama consists of a char-
acteristic double structure with
inner and outer membraneunits (ar-
rowheads) . Bar, 1Am . x24,000 . (B)
Purified human platelets were in-
cubated in buffer for 90 min at
37°C . Pseudopodal surface projec-
tions are evident ; the platelets (P)
containboth u granules (arrowheads)
and dense granules (arrows) in their
cytoplasm ; platelet aggregation was
not evident . Bar, 1 Am. x12,000 .
had numerous surface projections, and aggregation was not
evident (Fig. 2 B) .
When platelets were incubated with T . gondii at a ratio
of10:1 for 30 min, circumferential attachment of the platelets
by surface projections to the outermembrane of the parasites
was observed (Fig. 3,A and B) . The parasites exhibited marked
cytotoxic changes as a consequence of this interaction with
human platelets for 90 min (Fig . 4, A and B) . Swelling and
disruption of the parasite surface membrane structure was
noted (Fig . 4, A and B); the cytoplasm of the ToxoplasmaFigure 3 .
￿
Adherence of platelets to Toxoplasma . (A) Human platelets were incubated with Toxoplasma in a ratio of 10 :1 for 30 min as described
in Table 1 . Close apposition of platelet (P) pseudopodal projections (arrowheads) to the surface of the Toxoplasma (TOXO) is seen . Bar, 1 p.m . x40,000 .
(B) Platelet (P) adherence (arrowheads) to the surface membrane of the Toxoplasma was often extensive Bar, 1 1,m . x35,000 .
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￿
Platelet-induced Toxoplasma cytotoxicity. (A) Platelets and Toxoplasma (10 :1 ratio) were incubated for 90 min as described in Table 1 . Platelet
(P) aggregation and degranulation are evident with attachment (arrowheads) of platelet surface projections to the surface of the Toxoplasma (TOXO) .
Release of cytoplasmic contents (arrows) through the inner parasite membrane is associated with prominent bulging of the outer parasite membrane.
Bar, 1Am . x30,000 . (B) Additional cytotoxic changes noted in the Toxoplasma (TOXO) after their interaction with human platelets (P) include disrup-
tion of the surface membrane (arrowheads), swelling of the membrane surrounding the nucleus (N), and intracytoplasmic vacuolization with disappear-
ance of intracellular organelles (mitochondria, Golgi apparatus, and endoplasmic reticulum) . Bar, 1 A.m. x28,000.became vacuolated with loss of organelles (Fig. 4 B) . Other
cytotoxic changes noted in the T . gondii were dilation of their
nuclear envelope membranes and disruption of their inner
surface membranes; platelet aggregation was prominent in
the platelet-T gondii reaction mixtures.
Lack of Role of Reactive Oxygen Species in Cytotoxicity.
Studies were conducted to determine the biochemical mech-
anisms) ofplatelet cytotoxicity against T .gondii. Production
of small amounts of chemiluminescence (44, 45) and 01 (46)
by human platelets has been reported, and the possible con-
tribution of platelet generation of reactive oxygen species in
killing of Toxoplasma was examined. Human platelets, how-
ever, failed to reduce ferricytochrome c after incubation with
T. gondii (10:1 ratio) for 90 min at 370C (n = 3) indicating
a lack of 01 formation during this interaction. In addition,
platelets from a CGD patient effectively killed Toxoplasma
at platelet/T. gondii ratios from 1:1 to 100:1 at 60 and 90
min of incubation (Fig. 5).
Release of Cyclooxygenase Arachidonate Products during
Platelet-T gondii Interaction. The possible role of cycloox-
ygenase products of arachidonic acid metabolism in the medi-
ation of platelet cytotoxicity against T . gondii was studied.
As seen in Fig. 6, human platelets incubated in buffer alone
for 90 min released 34.8 pg TXB2 and 19.4 pg PGE2 per
106 platelets. PGE2 (73.4 pg/106 organisms) was the predom-
inant cyclooxygenase arachidonate product releasedby T . gondii
incubated in buffer alone for 90 min. When platelets were
incubated with Toxoplasma (1:1 ratio), TXB2 production was
augmented 3.9-fold (to a concentration of 4 x 10-9 M)
compared to TXB2 release by platelets alone (p < 0.02);
PGEZ release was not significantly altered from that of T.
gondii alone. The cyclooxygenase inhibitor indomethacin
(10-5 M) inhibited the release of TXB2 and PGEZ by the
plateletToxoplasma reaction mixtures by 89.0 and 72.6%,
respectively. Dazmegrel, a potent inhibitor of TXA2 synthe-
tase, has no significant activity against either cyclooxygenase
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Figure 5.
￿
Toxoplasmacidal activity of CGD platelets. Platelets from a
patient with CGD were incubated with T . gondii in PBS for 90 min at
37°C at the following ratios of platelets to Toxoplasma: 1:10 (O); 1:1(");
10:1(0); and 100:1(/). Viability ofthe organisms was assessedby trypan
blue staining. The data are the mean of two experiments using platelets
from a single patient with CGD.
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￿
Release of TXB2 and PGEZ by platelet-T gondii reaction mix-
tures. Supernatants were obtained from the following reaction mixtures
that were incubated in a final volume of 2 ml PBS for 90 min at 37°C:
2 x 107 platelets (Plts) (n - 12); 2 x 107 T. gondii (n - 18); 2 x 107
platelets and 2 x 107 T. gondii in the absence (n = 8) or presence of ei-
ther 10-5 M indomethacin (Indo) (n - 5) or 10- s M dazmegrel (Daz)
(n = 3); and 2 x 107 platelets that had been obtained from subjects who
had ingested 1.3 mg/kg of acetylsalicylic acid (ASA) 2 h before blood
collection and 2 x 107 T . gondii (n = 4). The supernatants were assayed
in 0.1-ml aliquots for TXB2 and PGEZ by RIA.
or PGI2 synthetase enzymes (25). Dazmegrel (10 -5 M) in-
hibited TXB2 release by 85.1% and stimulated PGEZ release
by 65.2% in the platelet-T gondii reaction mixtures. Platelets
were also isolated from individuals who had taken acetylsali-
cylic acid (1.3 mg/kg) 2 h before blood collection for in vivo
inhibition of cyclooxygenase activity (28). After interaction
with Toxoplasma, these platelets released < 7 pg of either
TXB2 or PGE2 per 0.1-ml sample containing 106 platelets
and 106 T . gondii. Less than 20 pg of 6-keto-PGFi« were
released per 0.1-ml sample containing 106 platelets and/or
Toxoplasma (data not shown).
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Toxoplasmacidal effect of CTA2. Toxoplasma (2 x 107 were
incubated for 90 min in the absence (O) or presence of CTA2 (2.9 x 10-8
M, &; 2.9 x 10-7 M, /; 2.9 x 10-6 M, 0; 2.9 x 10- 5 M, ") in
2 ml PBS for 90 min at 37°C. Viability of the T . gondii was assessed by
trypan blue staining. The data are the mean ± SE of three experiments.Thereaction mixtures contained 2 x 107 T. gondii (Toxo; RH strain) in the absence or presence of 2 x 108 platelets in 2 ml PBS. In some experi-
ments, indomethacin (Indo) or dazmegrel (Daz) at theindicated concentrations were included in the reaction mixtures. Platelets were also obtained
from individuals ingesting 1.3 mg/kg of acetylsalicylic acid (ASA) 2 h before blood collection. The supernatants were assayed in 0.1-ml aliquots
for TXBZ by RIA. The reaction mixtures were incubated for 90 min at 37°C with parasite viability assessed as described in Table 1.
' Mean ± SE of three experiments. Probability values for the difference from T. gondii alone (pl) and platelets plus T. gondii (p2) are shown where
significant (p < 0.05).
t Percent inhibition.
Role of TX Release in Platelet-induced Toxicity.
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Inhibition
of the cyclooxygenase pathway of arachidonic acid metabo-
lism blocked platelet-mediated parasite killing (Table 3).
Platelet-mediated toxoplasmacidal activity was inhibited in
Table 4.
￿
Interaction of T. gondii with Human Platelet Fractions:
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a concentration-dependent manner by indomethacin and daz-
megrel with 85.2 and 82.1% inhibition, respectively, at a
10 -5 M concentration of each inhibitor alone. A direct
correlation between degree of inhibition of TX release and
Cytotoxicity and Release of TX
The reaction mixture was as described for Table 1 except the following subcellular fractions representing material obtained from 2 x 108 human
platelets (prepared as described in Materials and Methods) were assayed for cytotoxicity against T. gondii (Toxo; 2 x 107) in a final volume of 2
ml for 90 min at 37°C as follows: thrombin (5 U/ml)-stimulated platelets or the following fractions of platelets disrupted by freezing and thawing:
entire contents; 100,000 g pellet (microsomes); and 100,000-g supernatant (microsome depleted). Control Toxoplasma were incubated in buffer alone
for 90 min at 37°C. Viability of organisms was assessed by trypan blue staining, and TXBZ was assayed by RIA.
Mean ± SE of experiments (n). Probability (p) values for the difference from T. gondii alone are shown where significant (p < 0.05) .
Table 3. Effect of
Supplements
Cyclooxygenase and Thromboxane
Nonviable T. gondii
Synthetase Inhibitors on Platelet Toxoplasmacidal Activity
TXB,
and TX Release
% P
1
P2 pg/0.1 ml P' P2
Toxo 5.3 ± 1.6' <0.001 4.3 ± 2.8` <0.01
Platelets + Toxo 60.3 ± 5.3 <0.001 184.7 ± 36.6 <0.01
+ Indo 8.9 ± 2.1 <0.001 14.0 ± 5.6 <0.02
(10-5 M) (85.2)t (92.4)t
+ Indo 8.0 ± 1.2 <0.001 18.8 ± 7.6 <0.02
(10-6 M) (86.7) (89.8)
+ Indo 22 .5 ± 2.9 <0.01 <0.01 39.7 ± 13.9 <0.05
(10- M) (62.7) (78.5)
+ Indo 46.0 ± 0.8 <0.001 159.0 ± 38.4 <0.02
(10-8 M) (23.7) (13.9)
+Daz 10.8±2.1 <0.001 16.0 ± 4.0 <0.02
(10-5 M) (82.1) (91.3)
+ Daz 12.1 ± 2.5 <0.002 22.7 ± 9.0 <0.02
(10-6 M) (79.9) (87.7)
+ Daz 44.2 ± 3.3 <0.001 112.0 ± 16.1 <0.01
(10- M) (26.7) (39.4)
Platelets (ASA) 8.5 ± 2.7 <0.001 0.3 ± 0.3 <0.01
+ Toxo (85.9) (99.8)
Supplements Nonviable T. gondii TXBZ
P pg/0.1 ml P
Toxo 8.6 ± 0.9 (5)' 10.4 ± 2.5 (5)
+ intact platelets 50.0 ± 12.5 (4) <0.01 244.4 ± 122.0 (4) <0.01
+ thrombin-stimulated platelets 39.1 ± 4.8 (3) <0.001 197.3 ± 68.1 (3) <0.01
+ freeze-thawed platelets:
entire contents 30.4 ± 2.7 (3) <0.001 130.7 t 11.6 (3) <0.001
100,000-g pellet 44.5 ± 13.2 (3) <0.02 214.3 ± 65.6 (3) <0.01
100,000-g supernatant 10.1 ± 0.5 (3) 19.3 ± 4.1 (3)Figure 8 .
￿
Effect of CTAZ and platelet microsomes on T, gondii morphology. Txoplasma (710XO) were incubated in buffer for 90 min at 37°C with
either (A and B) 2.9 x 10' 5 M CTAZ as described in Fig. 7 or (C) the 100,000 g pellet (microsomes) obtained from 2 x 108 platelets that had been
disrupted by freezing and thawing as described in Table 4 . As seen in A, CTAZ caused marked vesiculization of the surface membrane (arrows) and
dilation of the nuclear envelope (arrowheads) of the Toxoplasma . Lysis of Toxoplasma by the platelet microsome-containing particulate fraction is observed
inC . Extensive swelling (arrowheads) anddisruption of surface membranes with loss ofintracytoplasmic contents are noted . Surface membrane vesiculiza-
tion (arrows) is also evident . Bars, 1 )Am . (A) x30,000 ; (B) x42,000; (C) x40,000 .
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was observed (Table 3). Further, platelets obtained from in-
dividuals who had ingested acetylsalicylic acid before blood
collection failed to either exert a significant cytotoxic effect
or release TXBz after interaction with Toxoplasma (Table 3) .
Since TXAz is unstable with a short half-life of -30 s at
pH 7.4 and 37°C (47), the stable TX analogue CTAz (48)
and a platelet microsomal TXAz-generating system were ex-
amined for toxoplasmacidal activity. Incubationof Toxoplasma
with 2.9 x 10-7 M CTAz for 90 min resulted in killing of
22.7% of the organisms; cytotoxicity increased to 67.4% at
2.9 x 10 -5 M CTAz (Fig. 7). Ultrastructural studies (Fig.
8, A and B) showed that CTAz (2.9 x 10-5 M) induced
vesicle formation in the surface membranes of the Toxoplasma
and dilation of the perinuclear membranes of the organisms.
The entire contents of platelets disrupted either by treat-
ment with 5 U/ml thrombin for 15 min or by three cycles
of freezing and thawing over a 90-min period which com-
pletely releases the platelet cytoplasmic granule contents as
previously shown (14) caused a significant reduction in the
viability of the Toxoplasma and the respective release of 197.3
and 130.7 pg of TXBz per 0.1-ml sample (Table 4). The
platelets that had been disrupted by freezing and thawing
were centrifuged at 5,000g for 15 min. Additional centrifu-
gation of the supernatant at 100,000 g for 60 min produced
a microsome-containing particulate fraction and a microsome-
depleted supernatant as previously demonstrated (31). TX
synthetase, which is located in platelet microsomes (31, 32),
converts the unstable cyclic endoperoxides PGG2 and PGH2
to TXAz (31, 47). The presence of TXAz synthetase in the
microsome preparations was confirmed by the recovery of
398.0 ± 166.3 pg TXBz per 0.1-ml sample of the 100,000-g
pellet after incubation with 10 -5 M PGH2 for 90 min at
37°C (n = 3). The microsome-containing 100,000-g pellet
induced a significant increase in nonviability of the organisms.
Reaction mixtures containing the platelet 100,000-g partic-
ulate fraction and T gondii released 20.6-fold greater amounts
of TXBz than did T. gondii alone (Table 4). In contrast, the
100,000-g supernatant was ineffective in killing the Toxoplasma
and did not induce a significant increase in TXBz release
compared with reaction mixtures with T. gondii alone (Table
4). The toxoplasmacidal activity of the platelet microsomal
fractions was confirmed by transmission electron microscopy.
T. gondii, after incubation with platelet microsomes (Fig. 8
C), exhibited such cytotoxic changes as swelling of their sur-
face membranes and disruption of their intracellular organelles.
Discussion
These studies demonstrate that human platelets exert po-
tent cytotoxic activity against tachyzoites (i.e., the prolifer-
ating form) of the pathogenic protozoan, T. gondii. Platelet
toxoplasmacidal activity, like platelet tumoricidal activity (21),
occurs in the absence of added antibody. This is in contrast
to platelet-mediated ADCC against erythrocytes (13, 14) and
infective forms of S. mansoni (16) and x malayi (19) which
require either IgG or IgE antibody for cytotoxicity. Further,
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heat-inactivated sera containing Toxoplasma-specific IgG an-
tibodies in the absence or presence of Toxoplasma-specific IgM
antibodies had no effect on platelet-mediated toxoplasmacidal
activity. Platelet-mediated killing of Toxoplasma occurs at
platelet/T. gondii ratios as low as 1:3 with toxicity increasing
with higher ratios of platelets to organisms over a 90-min
period. Prior studies assayed platelet-mediated tumor cell cy-
totoxicity after a 48-h incubation period (21). Human
platelet-induced killing of T. gondii appears to require close
contact between effector and target cells since separation of
platelets from Toxoplasmaby a membrane filter abrogated cy-
totoxicity. Ultrastructural studies demonstrated initial adher-
ence of platelet pseudopodal projections to the surface of the
parasites which was followed by swelling of the outer para-
site membrane and intracellular cytolysis of the T . gondii. Toxo-
plasma after their interaction with platelets in vitro were un-
able to infect mice in vivo.
Destruction of T. gondii by human platelets was not medi-
ated by the release of toxic oxygen species by the platelets
since O generation by platelets after interaction with Toxo-
plasma was not observed and CGD platelets were cytotoxic
to the organisms. In addition, platelet granule contents were
not implicated in the cytotoxic process since the microsome-
depleted supernatant fractions containing granule material ob-
tained from platelets disruptedby freezing and thawing lacked
toxoplasmacidal activity. Slezak et al. (14) were similarly un-
able to demonstrate a role for either platelet-derived oxygen
radicals or granule components in platelet-mediated ADCC
against sheeperythrocytes. Our data suggest that TX gener-
ation may be important in the mediation of platelet killing
of Toxoplasma . Evidence in support of this role for TX is
as follows.
There was a 3 .9-fold increase in TXBz release by platelets
incubated with T. gondii (1:1 ratio) compared with platelets
incubated in buffer alone. Inhibition of platelet cyclooxygenase
either in vitro by indomethacin or in vivo by acetylsalicylic
acid inhibited platelet-mediated parasite killing and release
of TXBz . Further, the selective TX synthetase inhibitor daz-
megrel abrogated in vitro platelet-mediated killing of Toxo-
plasma. The selectivity of the inhibitory effect of dazmegrel
on TX synthetase vs. cyclooxygenase enzyme activity was
demonstrated by the inhibitory effect of dazmegrel on TXBz
release in contrast to its stimulatory effect on PGEz release
by the platelet-T gondii reaction mixtures. Although T. gondii
readily incorporate exogenously added arachidonic acid, the
Toxoplasma do not convert arachidonate into lipoxygenase
products (26). Generation of PGEz in the platelet-T gondii
preparations was presumablyfrom the organisms sinceT. gondii
incubated in buffer alone for 90 min released 73 .4 pg PGEz
per 0.1-ml sample containing 106 Toxoplasma. Whereas other
parasites such as Taenia taeniaeformis (49, 50) and S. mansoni
(51), as well as gram-negative and gram-positive bacteria (52),
release PGEz and other eicosanoids, formation of cycloox-
ygenase arachidonate products by T. gondii has not been de-
scribed previously to our knowledge.
Additional evidence for TXAz in the mediation of
platelet-induced cytotoxicity against T . gondii was providedby studies examining the cytotoxic effect ofthe TX analogue
CTAZ and microsome-containing fractions of disrupted
platelets. Although CTAZ lacks the platelet aggregatory ac-
tivity of TXA2, this stable TX analogue does exhibit the
potent vasoconstrictor activity of biologically generated
TXA2 (53, 54). Prior studies in cats have demonstrated that
CTAZ infusion damages myocardial cell membranes with re-
lease of myocardial creatine kinase and lysosomal hydrolase
activities (54). We found that CTAZ and platelet microsomes
capable of releasing TX produced extensive surface and
perinuclear membrane damage in the Toxoplasma and induced
significant nonviability of the organisms. Since T. gondii form
PGE2, it is possible that the organisms provide the cyclic en-
doperoxideprecursor (PGG2/PGH2) required by TXA2 syn-
thetase present in the platelet microsomes to generate TX.
CTAZ-induced Toxoplasma cytotoxicity was observed be-
ginning at a concentration of 2.9 x 10-7 M which is com-
parable to the 2 x 10-1 M CTAZ concentration that stimu-
lates the release of lysosomal hydrolases from large granule
fractions of liver homogenate (53) . In the platelet-T gondii
(1:1 ratio) reaction mixtures, generation of 4 x 10 -9 M TX
(Fig. 6) was associated with significant parasite cytotoxicity
(Table 1). The greater reactivity of TX in comparison to
CTAZ in induction of Toxoplasma cytotoxicity may result
from a unique structural feature of TXA2 . TXA2 has an
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